AMOEBA : Availability of the 2022 Universal Registration Document
AMOÉBA announces the availability of the 2022 Universal Registration Document including the Annual Financial Report
Lyon (France), April 18, 2023 -5.45 pm- AMOÉBA (FR0011051598 – ALMIB), an industrial biotech in pre-commercialization* specialized in the treatment of microbiological risk, developing a biocontrol agent for the treatment of plants in agriculture and a biological biocide for the treatment of industrial water , announces that the 2022 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers-AMF) on April 18, 2023 under number D.23-0296.
The 2022 Universal Registration Document includes:
- the Annual Financial Report comprising the consolidated financial statements, the parent company financial statements, the management report and the related statutory auditors’ reports
- The Board of Directors’ corporate governance report
The Universal Registration Document 2022 also presents the company’s activities, particularly in the development of the biocidal and biocontrol applications and its research works. The organisation, financial situation, results and prospects of Amoéba are also described in the Document.
The document may be viewed or downloaded on the company’s website www.amoeba-nature.com under section “Investors / financial documents/ Reference Document”. Copies of the Universal Registration Document are also available at the company’s headquarters: 38, avenue des frères Montgolfier, 69680 Chassieu, France.
Next event: General Meeting of Shareholders: 25 May 2023